fispemifene

Small moleculeexperimental

Fispemifene is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed for the treatment of male hypogonadism but was abandoned and never marketed. It reached phase II clinical trials for this indication before development was terminated in March 2016. The drug failed to achieve statistical significance on key effectiveness endpoints in clinical trials and was discontinued by its developer for strategic reasons. — Wikipedia

Clinical trial activity

4 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Feb 1, 2006 (NCT00290134)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

OCCOCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1
Mol. weight
422.95 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • fispemifene
  • fispemifene
  • fispemifene
  • fispemifene
  • hm-101
  • hm-101
  • hm-101a
  • hm-101a
  • (z)-2-(2-(4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy)ethoxy)ethanol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02443090Phase 2May 1, 2015Apricus Biosciences
NCT01061970Phase 2Jan 1, 2007Hormos Medical, Quatrx Pharmaceuticals Co
NCT00415571Phase 2Dec 1, 2006Hormos Medical, Quatrx Pharmaceuticals Co
NCT00290134Phase 2Feb 1, 2006Hormos Medical, Quatrx Pharmaceuticals Co
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hormos MedicalFor profit3012006
Quatrx Pharmaceuticals CoFor profit3312006
Apricus BiosciencesFor profit1112015
3 organizations
Page 1 / 1